Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
by Zacks Equity Research
Key highlights of the past week are collaborations and pipeline updates.
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
CELG or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
by Zacks Equity Research
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments.
CELG vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
Why Is Vertex (VRTX) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.
Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are merger agreements, and regulatory and pipeline developments.
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
The Zacks Analyst Blog Highlights: Nike, 3M, Vertex, PepsiCo and Verisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nike, 3M, Vertex, PepsiCo and Verisk
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
Top Stock Reports for Nike, 3M & Vertex
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Nike (NKE), 3M (MMM) and Vertex (VRTX).
Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Groupon (GRPN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Groupon (GRPN) rides on partnership with Grubhub along with ongoing brand awareness programs. Further, launching new products on a regular basis is a positive.
Factors Likely to Influence Cisco's (CSCO) Earnings in Q2
by Zacks Premium Research
Cisco (CSCO) to benefit from acquisition synergies and strength in the it's Security and Applications segments.
Factors Expected to Influence Akamai's (AKAM) Q4 Earnings
by Zacks Equity Research
Akamai (AKAM) benefits from the robust performance of security products and growth in Media and Carrier Division.
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales
by Zacks Equity Research
Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.